Form 8-K - Current report:
SEC Accession No. 0001493152-21-028333
Filing Date
2021-11-15
Accepted
2021-11-15 08:00:21
Documents
15
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40223
2 ex99-1.htm EX-99.1 50916
3 ex99-1_001.jpg GRAPHIC 2615
  Complete submission text file 0001493152-21-028333.txt   314763

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE avte-20211115.xsd EX-101.SCH 3269
5 XBRL DEFINITION FILE avte-20211115_def.xml EX-101.DEF 26194
6 XBRL LABEL FILE avte-20211115_lab.xml EX-101.LAB 35952
7 XBRL PRESENTATION FILE avte-20211115_pre.xml EX-101.PRE 24852
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4762
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 211406423
SIC: 2834 Pharmaceutical Preparations